Mehmet KALAYCI, Emine TUGBA ALATAS, Asude KARA POLAT, Gursoy DOGAN, Asli AKIN BELLI

Plasma and salivary irisin levels in lepramatous leprosy patients

Aim: We aimed to investigate the plasma and salivary irisin levels in leprosy patients, as well as to evaluate the role of the irisin inthe leprosy pathogenesis. Leprosy is a granulomatous disease with the peripheral nerves, mucous membrane, and skin involvementprimarily. Irisin, a novel protein, has been associated with several inflammatory diseases and demonstrated in the peripheral nervecells, deep sebaceous glands, and saliva excessively. To our knowledge, there is no study investigating the irisin levels in patientswith leprosy.Material and Methods: We conducted a case-control study on 20 patients with lepromatous leprosy and 20 healthy controls betweenJanuary 2016 and January 2017. Of the participants, the demographic data and disease history including duration of the disease,any current treatments, and presence of any other family members with leprosy were recorded. The plasma and salivary irisin levelsof the participants were measured by enzyme-linked immunosorbent assay (ELISA). Additionally, the serum levels of C-reactiveprotein (CRP), glucose, hemoglobin A1c (HbA1C), triglyceride, cholesterol, high-density lipoprotein (HDL) and low-density lipoprotein(LDL) were evaluated in both groups.Results: The plasma and salivary irisin levels were significantly lower in the patient group than those in the control group (P = 0.001and P = 0.03, respectively). In patients with leprosy, the serum and salivary irisin levels had a positive correlation (r: 576, p: 0.008). Inaddition, there was a negative correlation between the plasma irisin and CRP levels (r: −468, p: 0.037).Conclusion: The irisin may act an immunomodulatory role in leprosy. The irisin production is probably suppressed by the increasedinflammatory markers in leprosy or the bacillus to reach the temperature for its reproduction. Further studies are needed to clarifythe role and prognostic value of the irisin in leprosy with a large number of patients examined before and after the treatments.

PDF

___

1. Pereira RM, Calegari-Silva TC, Hernandez MO, et al. Mycobacterium leprae induces NF-kappaB-dependent transcription repression in human Schwann cells. Biochem Biophys Res Commun 2005;335:20-6.
2. Lockwood DNJ. Leprosy. In: Burns DA, Breatnach SM, Cox N, Griffits CE, et al, editors. Rook’s text book of dermatology. 7th edition. Oxford: Blackwell Publishing 2004;1-21.
3. Rea TH, Modlin RL. Leprosy. In: Wolf K, Goldsmith LA, Karz S, Gilchrest BA, Paller AS, Leffell DJ, et al, editors. Dermatology in General Medicine. 7th edition. New York: McGraw Hill Professional 2008;1786-96.
4. Bostrom P, Wu J, Jedrychowski MP, et al. A PGC1- alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012;481:463-8.
5. Norheim F, Langleite TM, Hjorth M, et al. The effects of acute and chronic exercise on PGC-1alpha, irisin and browning of subcutaneous adipose tissue in humans. FEBS J 2014;281:739-49.
6. Alatas ET, Kalayci M, Kara A, et al. Association between insülin resistance and serum and salivary irisin levels in patients with psoriasis vulgaris. Dermatologica Sinica 2017;35:12-5.
7. Hojlund K, Boström P. Irisin in obesity and type 2 diabetes. J Diabetes Complications 2013;27:303-4.
8. Gagnini M, Cabiati M, Del Turco S, et al. Increased FNDC5/Irisin expression in human hepatocellular carcinoma. Peptides 2017;88;62-6.
9. Aydin S, Kuloglu T, Aydin S, et al. Cardiac and skeletal muscle serum irisin responses to with or without water exercise in young and old male rats: cardiac muscle produces more irisin than skeletal muscle. Peptides 2014;52:68-73.
10. Aydin S, Aydin S, Kobat MA, et al. Decreased saliva/ serum irisin concentrations in the acute myocardial infarction promising for being a new candidate biomarker for diagnosis of this pathology. Peptides 2014:56;141-5.
11. Ramos-e-Silva M, Ribeiro de Castro MC. Dermatology. In: Bolognia JL, Jorizzo JL, Rapini RP, et al, editors. Leprosy. 3rd edition. Philadelphia: Elsevier Saunders 2012;1221-42.
12. Lopez-Legarrea P, de la Iglesia R, Crujeiras AB, et al. Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects. Nutr Diabetes 2014;4:110.
13. Shi X, Lin M, Liu C, et al. Elevated circulating irisin is associated with lower risk of insulin resistance: Association and path analyses of obese Chinese adults. BMC Endocr Disord 2016;16:44.
14. Chen JQ, Huang YY, Gusdon AM, et al. Irisin: a new molecular marker and target in metabolic disorder. Lipids Health Dis 2015;14:2.
15. Park MJ, Kim DI, Choi JH, et al. New role of irisin in hepatocytes: The protective effect of hepatic steatosis in vitro. Cell Signal 2015;27:1831-9.
16. Liu JJ, Wong MD, Toy WC, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications 2013;27:365-9.
17. Lee MJ, Lee SA, Nam BY, et al. Irisin, a novel myokine is an independent predictor for sarcopenia and carotid atherosclerosis in dialysis patients. Atherosclerosis 2015; 242:476-82.
18. Wen MS, Wang CY, Lin SL, et al. Decrease in irisin in patients with chronic kidney disease. PLoS ONE 2013; 8:64025.
19. Polak K, Czyzyk A, Simoncini T, et al. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Investig 2017;40:1-8.
20. Polyzos SA, Kountouras J, Anastasilakis AD, et al. Irisin in patients with nonalcoholic fatty liver disease. Metabolism 2014;63:207-17.
21. Dulian K, Laskowski R, Grzywacz T, et al. The whole body cryostimulation modifies irisin concentration and reduces inflammation in middle aged, obese men. Cryobiology 2015;71:398-404.
22. Hou N, Han F. Sun X. The relationship between circulating irisin levels and endothelial function in lean and obese subjects. Clin Endocrinol 2015;88:339-43.
23. Xiang L, Xiang G, Yue L, et al. Circulating irisin levels are positively associated with endothelium-dependent vasodilation in newly diagnosed type 2 diabetic patients without clinical angiopathy. Atherosclerosis 2014;235:328-33.
24. Gannon NP, Vaughan RA, Garcia-Smith R, et al. Effects of the exercise- inducible myokine irisin on malignant and non-malignant breast epithelial cell behavior in vitro. Int J Cancer 2015;136:197-202.
25. Mazur-Bialy AI. Irisin acts as a regulator of macrophages host defense. Life Sci 2017;176:21.
26. Ernst JD. Leprosy (HansenDisease). In: Goldman L, Schafer AI, et al, editors. Goldman’s Cecil Medicine. 25th edition. Philadelphia: ElsevierSaunders; 2016;326:2042-6.
27. Chang JS, Kim TH, Nguyen TT, et al. Circulating irisin levels as a predictive biomarker for sarcopenia: A cross-sectional community-based study. Geriatr Gerontol Int 2017;17:2266-73.
28. Albayrak S, Atci IB, Kalayci M, et al. Effect of carnosine, methylprednisolone and their combined application on irisin levels in the plasma and brain of rats with acute spinal cord injury. Neuropeptides 2015;52:47- 54.